COLLECTED BY SARAH MOSS
RESEARCH CORNER A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma.
In the Clinical trial done by GWpharmaceuticals using Sativex ( a cannabis extract of equal parts THC and CBD) and temozolomide in recurrent glioblastoma multiforme. Editors Note | Recurrent Glioblastoma (the cancer Senator John McCain had).
STUDY FACTS The median survival rate of those: 1. in the placebo group was around 369 days 2. in the sativex and temozolomide group was greater than 550 days
The 1 year survival rate of those: 1. in the placebo group was 56% 2. in the sativex and temozolomide group was 83% In the review of the clinical trial it concluded the the CBD:THC offers “some efficacy� in the treatment of recurrent glioblastoma multiforme with used in conjunction with dose- intense temozolomide.
16
